Tumgik
#vyepti
headpainmigraine · 11 months
Text
I say a lot of crap about GP's on this blog because of the many, many, MANY bad experiences I've had with them (shout out to the one good doctor I had before I moved, who I love and miss very much)
I find I get better treatment when I get past the GP to the specialists, some of the time, but I get the feeling that they're happy to see you, but immediately lose interest if your issue isn't shown in tests and/or something with an easy fix. The postcare isn't very good, is what I'm getting at.
My neuro team are fantastic. They can't respond to my emails very quickly because they're critically overworked, but I feel like they really actually care. They even remember me. I mean...
Anyway!
I had my Vyepti treatment a few months ago and had a call about where we go from here.
I haven't had a reduction in migraine days, still getting one every day, but my medication use dropped by half (!) and the severity went from an average of 8 to an average of 6
That's a HUGE improvement for me, and one I've never had from any other treatment so far. The effect is truly massive.
I don't meet the NICE criteria for a second dose, because I haven't had a reduction in my headache days, or a significant enough drop in severity ;_;
HOWEVER, my headache nurse is going to fight for me to get a second dose.
Nothing has worked as well for me in 8 years, I mean.
If she's successful, I might be getting another dose in August, otherwise...?
((We also discussed if the way autoimmune autonomic ganglionopathy works might be why I don't respond to any treatments, but she couldn't answer that. If my neuro is around when I go down for my treatment, she said I could discuss it with him ))
All over, I'm feeling optimistic!
4 notes · View notes
angelictrancy · 9 months
Text
Tumblr media
Uhg there is an itch.... under all that tape.....
Tumblr media
6 notes · View notes
ecoamerica · 2 months
Text
youtube
Watch the American Climate Leadership Awards 2024 now: https://youtu.be/bWiW4Rp8vF0?feature=shared
The American Climate Leadership Awards 2024 broadcast recording is now available on ecoAmerica's YouTube channel for viewers to be inspired by active climate leaders. Watch to find out which finalist received the $50,000 grand prize! Hosted by Vanessa Hauc and featuring Bill McKibben and Katharine Hayhoe!
16K notes · View notes
wiseoldowl72 · 2 years
Photo
Tumblr media
Infusion done. No side effects. Migraine day anyway. Can see it in my eyes. I saved my @radiocomusic "City Grown Willow" tee for support. . . #lifeonosage #family #migraine #invisibledisease #infusion #vyepti #radiocomusic (at North Kansas City Hospital) https://www.instagram.com/p/CjbLC9eOtu4/?igshid=NGJjMDIxMWI=
2 notes · View notes
mental-mona · 2 months
Text
0 notes
lazyai · 2 years
Text
vyepti ads r back
0 notes
morosexualharrow · 3 months
Text
when my neurologist told me that some people feel pain relief during the infusion itself while we were talking about switching me from botox to vyepti I was certain that she was full of shit or mentioning like an edge case to try to make me feel better because I was crying over how bad my head always hurts but I got my first infusion on Tuesday and it broke my migraine in a way that even the last couple of times that I've gone to the emergency room for a migraine cocktail didn't touch. I've been sleeping so much but it feels like catching up on sleep kind of sleeping so much and not the can't tolerate being alive and awake sleeping so much. I just ran an errand and walked a mile home instead of taking an Uber and usually just the Uber there and back means that I have to take a huge nap.
6 notes · View notes
ecoamerica · 1 month
Text
youtube
Watch the 2024 American Climate Leadership Awards for High School Students now: https://youtu.be/5C-bb9PoRLc
The recording is now available on ecoAmerica's YouTube channel for viewers to be inspired by student climate leaders! Join Aishah-Nyeta Brown & Jerome Foster II and be inspired by student climate leaders as we recognize the High School Student finalists. Watch now to find out which student received the $25,000 grand prize and top recognition!
17K notes · View notes
aibidil · 2 years
Text
Tumblr media
Y'all I think my Tumblr ads are haunted because I cannot stop accidentally clicking this fucking vyepti ad. (It isn't 73 tabs of vyepti. I promise.)
4 notes · View notes
akirashiratori · 2 years
Text
vyepti ads punishing tumblr users for having finger pads
2 notes · View notes
headpainmigraine · 10 months
Text
This flu thing is kicking my ass. My nose keeps bleeding, my lips are split, my throat hurts and my earache keeps pulling me to the left. I can't stay awake more than 3 hours at a time.
But!
I got a second Vyepti treatment on the 14th!!
Gotta bring my nurse flowers for getting them to let me have a second dose.
3 notes · View notes
angelictrancy · 1 year
Text
Tumblr media Tumblr media
Medication time!
5 notes · View notes
wiseoldowl72 · 2 years
Photo
Tumblr media
My first infusion of Vyepti. The latest and greatest for daily chronic migraines. Im doing wee, but still having daily headaches really hoping this will work better than any of the CGRP injectibles I had to go through to get here. Wish me luck. . . On a positive note. I did not use valet parking and walked from the garage to the outpatient treatment room. Small steps are paying off. . . #lifeonosage #family #vyepti #migraine #chronicmigraine #AKF #keepingitreal #unbreakable (at North Kansas City, Missouri) https://www.instagram.com/p/CjbETqfrERF/?igshid=NGJjMDIxMWI=
0 notes
newswireml · 1 year
Text
Nice approves new migraine drug for NHS use in England and Wales | NHS#Nice #approves #migraine #drug #NHS #England #Wales #NHS
Thousands of people in England and Wales who suffer from migraines could benefit from a drug that has been approved on the NHS. The National Institute for Health and Care Excellence (Nice), the drugs regulator, said it was recommending eptinezumab for preventing migraine in about 164,000 adults where at least three previous preventive treatments had failed. The drug, also called Vyepti, is taken…
View On WordPress
0 notes
cricsart · 1 year
Link
The major US HCP branded websites for migraine are Nurtec-hcp.com, Vyeptihcp.com, Quliptahcp.com, Ajovyhcp.com, Aimovighcp.com, and Ubrelvyhcp.com. Biohaven’s Nurtec-hcp.com had the highest number of visits among top migraine websites for HCPs in the US, followed by Lundbeck’s Vyeptihcp.com. Nurtec-hcp.com had the highest proportion of total traffic, followed by Vyeptihcp.com. Amgen’s Aimovighcp.com had the longest average website visit duration while Teva’s Ajovyhcp.com had both the highest number of pages per visit and the lowest bounce rate.
0 notes
maisuria · 1 year
Text
Role of Non-opioid Analgesics in the Chronic Pain Treatment Landscape
What are the recent developments in Chronic Pain Treatment Landscape? 
How will the recent developments help in the Chronic Pain Treatment Landscape?
Game changing developments in the Chronic Pain Treatment Landscape 
Role of Non-opioid Analgesics in the Chronic Pain Treatment Landscape 
Chronic Pain Treatment Market: Game changer developments and Major Growth Factors 
Key Companies Developing Therapies in the Chronic Pain Treatment Landscape 
Major Growth Factors and Developments Transforming the Clinical Diagnostics Market Landscape 
What is Chronic Pain and use of Non-opioid Analgesics in the Chronic Pain Treatment? 
What are the Major Growth Factors in Chronic Pain Market Landscape? 
Evaluating the Major Growth and Ongoing Developments in the Chronic Pain Market 
Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
What is Chronic Pain?
Chronic pain is a pain that lasts for more than three months. It can gradually grow and recur intermittently, outlasting the normal recovery process and adversely affecting the person’s well-being. Pain is supposed to cease after damaged tissue recovers until the root cause is treated.
The most common reason for adult impairment in the United States is chronic pain. There are currently 50 million Americans who have chronic pain. Lower back issues, arthritis, cancer, RSDS, repetitive stress disorders, shingles, headaches, and fibromyalgia are the most typical causes of chronic pain. Others include neurological disorders like phantom limb sensation and diabetic neuropathy. One of the most typical causes of chronic pain in people in their twenties is sports injuries. Every year, chronic pain costs society more than $100 billion.
Emgality (galcanezumab-gnlm), Aimovig (Eptinezumab), Tarlige (Mirogabalin besylate), Aimovig (Erenumab-aooe), Ajovy (Fremanezumab), Vyepti (Eptinezumab), and Pennsaid gel are just a few of the medications that have been approved for the treatment of chronic pain due to various indications.
Despite debates, opioids are thought to be the most effective drug for treating chronic pain. The purpose of managing chronic pain is to reduce symptoms and raise a person's level of functioning in daily activities. 
Musings on the chronic pain treatment 
The high prevalence of chronic pain among cancer patients is nothing new, but non-cancer people with a range of illnesses have also been found to experience chronic pain. It has been found that a significant portion of people with chronic pain experience osteoarthritis-related pain. Due to the disease's crippling effects on the cartilage between the joints, joints become excruciatingly painful.
Paradigm Biopharmaceuticals is creating ZILOSUL to fill the voids in the osteoarthritis treatment market. A semi-synthetic medication called pentosan polysulfate sodium (PPS) is made from the wood chips of European beech trees. The anti-inflammatory, tissue-regenerating, and somewhat anti-thrombotic effects of PPS activity are noteworthy.
In addition, a number of other industry titans, including AbbVie, Tonix Pharmaceuticals, Pfizer, Centrexion Therapeutics, Anika Therapeutics, Vertanical GmbH, Braeburn Pharmaceuticals, Grünenthal GmbH, Regeneron, Teva Pharmaceuticals, Biogen, and others, are looking into their respective candidates in a number of clinical trials for the treatment and management of chronic pain in the 7MM.
With new treatments like QULIPTA, TNX-102, reboxetine, CNTX-4975, CINGAL, dronabinol, buprenorphine, RTX-GRT7039, fasinumab, BIIB074, and others, the chronic pain pipeline appears to be promising.
The chronic pain treatment market is all set to grow significantly
The market landscape for treating chronic pain will change significantly over the forecast period as a result of the development of disease-specific chronic pain therapies. With better diagnosis and safe and effective chronic pain treatment options, the market for treating chronic pain is anticipated to increase dramatically.
However, there are two key concerns that affect the success of the new therapies in the chronic pain treatment market: difficulties with pricing and reimbursement, as well as related long-term side effects of approved medications.
To know more about the Non-opioid Analgesics Chronic Pain Treatment, read our blog; https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Related Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
"DelveInsight’s ‘Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast – 2027’ report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
DelveInsight’s ‘Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market 
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 
Latest Reports by DelveInsight
Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market |  Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services
Also, take a glance at the Blogs by DelveInsight:
Insights Into The Cutaneous T-cell Lymphoma Treatment Market https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Emerging Role of Digital Health in the Field of Oncology https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
How are Technological Trends and Innovations Reshaping the Dementia Care https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
0 notes
brokenbellz · 2 years
Text
IF I ACCIDENTALLY CLICK ONE MORE OF THESE VYEPTI ADDS I SWEAR TO FUCKING GOD
1 note · View note
lazyai · 2 years
Text
update: no more vyepti BUT now i have Xywav
0 notes